Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-20
1998-05-19
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514405, A61K 31415
Patent
active
RE0358010
ABSTRACT:
A prophylactic and therapeutic agent for circulatory disorders, comprising a pyrazolone derivative of the formula: ##STR1## wherein R.sub.1 represents a hydrogen atom, an aryl group, an alkyl group having 1 to 5 carbon atoms or an alkoxycarbonylalkyl group having a total carbon number of 3 to 6; R.sub.2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group having 1 to 5 carbon atoms or hydroxyalkyl group having 1 to 3 carbon atoms or R.sub.1 and R.sub.2 taken together represent an alkylene group having 3 to 5 carbon atoms; R.sub.3 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 7 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, a benzyl group, a naphthyl group, or a phenyl group which is unsubstituted or substituted with 1 to 3 substituents which are the same or different selected from the group consisting of alkyl groups having 1 to 5 carbon atoms, alkoxy groups having 1 to 5 carbon atoms, hydroxyalkyl groups having 1 to 3 carbon atoms, alkoxycarbonyl groups having total carbon number of 2 to 5, alkylmercapto groups having 1 to 3 carbon atoms, alkylamino groups having 1 to 4 carbon atoms, dialkylamino groups having total carbon number of 2 to 8, halogen atoms, trifluoromethyl group, carboxyl group, cyano group, hydroxyl group, nitro group, amino group and acetamide group, or a pharmaceutically acceptable salt thereof as an active ingredient. The agent of the present invention is useful as a prophylactic and therapeutic agent for circulatory disorders, particularly as an inhibitor against lipid peroxidation and/or an agent for normalizing cerebral dysfunctions.
REFERENCES:
patent: 3514465 (1970-05-01), Posselt et al.
patent: 3658845 (1972-04-01), Posselt et al.
patent: 3781439 (1973-12-01), Zoni et al.
patent: 4000294 (1976-12-01), Moller et al.
patent: 4005215 (1977-01-01), Moller et al.
patent: 4053621 (1977-10-01), Moller et al.
patent: 4112227 (1978-09-01), Moller et al.
patent: 4288446 (1981-09-01), Moller et al.
patent: 4670460 (1987-06-01), Mardin et al.
patent: 4698344 (1987-10-01), Sasse
Failure of Nafazatrom to Reduce Infarct Size and Arrhythmias in a Porcine Model of Acute Coronary Occlusion, V.B. Fiedler, European J. of Pharmac. 114 (1985) 189-195.
Microsomal N-Hydroxylation of Trans 4'-Alkoxy-4-Acetamidostilbenes, R.E. Gammans, et al. Drug Metabolism and Disposition vol. 6, No. 3., 226-231 (1983).
Chem. Abst. 73:45404h, (1970) Williams et al.
Chem. Abst. 101:222712(b), (1984) Mardin et al.
Chem. Abst. 102:17649r. (1985) Moeller et al.
Chem Abstracts 102:56154v. (1985)--Bayer, A.G.
"Stroke" vol. 8, No. 1, Jan.-Feb. 1977 pp. 51-57.
Cardiovascular Research 14. (1980):pp. 371-395.
Iseki Katsuhiko
Morinaka Yasuhiro
Nakajima (nee Sakurai) Hiroko
Nishi Hiroyoshi
Watanabe Toshiaki
Conlin David G.
Mitsubishi Chemical Corporation
Neuner George W.
Weddington Kevin E.
LandOfFree
Prophylactic and therapeutic composition for circulatory disorde does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prophylactic and therapeutic composition for circulatory disorde, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prophylactic and therapeutic composition for circulatory disorde will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1843676